Protein-coated nanoparticles embedded in films as delivery platforms

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 6, 2013, Pages 827-838

  Morales, Javier O ^a,c   Ross, Alistair C ^d   McConville, Jason T ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF CHILE   (Chile)

^d Ferring Controlled Therapeutics Limited   (United Kingdom)

Author keywords

antisolvent precipitation; buccal delivery; enzyme activity; films; protein coated nanoparticles

Indexed keywords

BUFFER; DRUG CARRIER; EUDRAGIT; HYDROXYPROPYLMETHYLCELLULOSE; LYSOZYME; NANOPARTICLE; PHOSPHATE; POLYMETHACRYLIC ACID;

ARTICLE; CHEEK MUCOSA; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME ACTIVITY; ENZYME RELEASE; MACROMOLECULE; MOLECULAR STABILITY; MUCOADHESION; PARTICLE SIZE; PERFORMANCE; PH; SOLUBILITY; ZETA POTENTIAL;

ADMINISTRATION, BUCCAL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HYDROGEN-ION CONCENTRATION; KINETICS; MACROMOLECULAR SUBSTANCES; METHYLCELLULOSE; MURAMIDASE; NANOPARTICLES; PARTICLE SIZE; POLYMETHACRYLIC ACIDS; PROTEINS; SOLUBILITY; WATER;

EID: 84877575080     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12046     Document Type: Article

References (44)

1. Tan ML, et al. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 2010; 31: 184-193.
2. Frokjaer S, Otzen DE,. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005; 4: 298-306.
3. Wang W,. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 1999; 185: 129-188.
4. Polonsky WH, et al. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care 2005; 28: 2543-2545.
5. Simmons JH, et al. Reliability of the diabetes fear of injecting and self-testing questionnaire in pediatric patients with type 1 diabetes. Diabetes Care 2007; 30: 987-988.
6. Rubin RR, et al. Barriers to insulin injection therapy. Diabetes Educ 2009; 35: 1014-1022.
7. Müller G,. Oral delivery of protein drugs: driver for personalized medicine. Curr Issues Mol Biol 2011; 13: 13-24.
8. Singh R, et al. Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci 2008; 97: 2497-2523.
9. Heinemann L, Jacques Y,. Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol 2009; 3: 568-584.
10. Pather SI, et al. Current status and the future of buccal drug delivery systems. Expert Opin Drug Deliv 2008; 5: 531-542.
11. Salamat-Miller N, et al. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev 2005; 57: 1666-1691.
12. Morales JO, McConville JT,. Manufacture and characterization of mucoadhesive buccal films. Eur J Pharm Biopharm 2011; 77: 187-199.
13. Perumal VA, et al. Investigating a new approach to film casting for enhanced drug content uniformity in polymeric films. Drug Dev Ind Pharm 2008; 34: 1036-1047.
14. Ibrahim MA, et al. Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J Control Release 2005; 106: 241-252.
15. Cui F, et al. Preparation and evaluation of chitosan- ethylenediaminetetraacetic acid hydrogel films for the mucoadhesive transbuccal delivery of insulin. J Biomed Mater Res A 2009; 89A: 1063-1071.
16. Giovino C, et al. Development and characterisation of chitosan films impregnated with insulin loaded PEG-b-PLA nanoparticles (NPs): a potential approach for buccal delivery of macromolecules. Int J Pharm 2012; 428: 143-151.
17. Nikolic K, et al. Self-assembly of nanoparticles on the surface of ionic crystals: structural properties. Surf Sci 2007; 601: 2730-2734.
18. Kreiner M, et al. DNA-coated microcrystals. Chem Commun 2005; 21: 2675-2676.
19. Morales JO, et al. The influence of recrystallized caffeine on water-swellable polymethacrylate mucoadhesive buccal films. AAPS PharmSciTech 2013. In press.
20. Morales JO, et al. A design of experiments to optimize a new manufacturing process for high activity protein-containing submicron particles. Drug Dev Ind Pharm 2013. In press.
21. Shugar D,. The measurement of lysozyme activity and the ultra-violet inactivation of lysozyme. Biochim Biophys Acta 1952; 8: 302-309.
22. Parikh NH, et al. Tensile properties of free films cast from aqueous ethylcellulose dispersions. Pharm Res 1993; 10: 810-815.
23. Okhamafe AO, York P,. Stress crack resistance of some pigmented and unpigmented tablet film coating systems. J Pharm Pharmacol 1985; 37: 449-454.
24. Costa P, Sousa Lobo JM,. Modeling and comparison of dissolution profiles. Eur J Pharm Biopharm 2001; 13: 123-133.
25. Tiyaboonchai W, et al. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007; 337: 299-306.
26. Schubert MA, Müller-Goymann CC,. Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm 2005; 61: 77-86.
27. Kreiner M, et al. Enzyme-coated micro-crystals: a 1-step method for high activity biocatalyst preparation. Chem Commun 2001; 12: 1096-1097.
28. Jores K, et al. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 2004; 95: 217-227.
29. Mora-Huertas CE, et al. Polymer-based nanocapsules for drug delivery. Int J Pharm 2010; 385: 113-142.
30. Murdan S, et al. Immobilisation of vaccines onto micro-crystals for enhanced thermal stability. Int J Pharm 2005; 296: 117-121.
31. Colombo P,. Swelling-controlled release in hydrogel matrices for oral route. Adv Drug Deliv Rev 1993; 11: 37-57.
32. Ham AS, et al. Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm Res 2012; 29: 1897-1907.
33. Smart JD,. The role of water movement and polymer hydration in mucoadhesion. In:, Mathiowitz E, et al., ed. Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and Development. New York: Marcel Dekker Inc, 1999: 11-23.
34. Panomsuk SP, et al. A study of the hydrophilic cellulose matrix: effect of drugs on swelling properties. Chem Pharm Bull 1996; 44: 1039-1042.
35. Nafee NA, et al. Mucoadhesive buccal patches of miconazole nitrate: in vitro/in vivo performance and effect of ageing. Int J Pharm 2003; 264: 1-14.
36. Asane GS, et al. Polymers for mucoadhesive drug delivery system: a current status. Drug Dev Ind Pharm 2008; 34: 1246-1266.
37. Wong CF, et al. Formulation and evaluation of controlled release Eudragit buccal patches. Int J Pharm 1999; 178: 11-22.
38. Peh KK, Wong CF,. Polymeric films as vehicle for buccal delivery: swelling, mechanical, and bioadhesive properties. J Pharm Pharm Sci. 1999; 2: 53-61.
39. Perumal VA, et al. Formulation of monolayered films with drug and polymers of opposing solubilities. Int J Pharm 2008; 358: 184-191.
40. Omari DM, et al. Lactic acid-induced modifications in films of Eudragit RL and RS aqueous dispersions. Int J Pharm 2004; 274: 85-96.
41. Moore JW, Flanner HH,. Mathematical comparison of dissolution profiles. Pharm Tech 1996; 20: 64-74.
42. Hassan MA, et al. Formulation and in vitro/in vivo evaluation of naproxen mucoadhesive buccal patches for local effect. J Drug Deliv Sci Technol 2011; 21: 423-431.
43. Averineni RK, et al. Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. Pharm Dev Technol 2009; 14: 199-207.
44. Korsmeyer RW, et al. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15: 25-35.